5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake.

D A Gorard, G W Libby, M J Farthing

Department of Gastroenterology, St Bartholomew's Hospital, London.

Parenteral 5-hydroxytryptamine stimulates small intestinal motility, but the effect of continuous stimulation with 5-hydroxytryptamine on the human migrating motor complex is unknown. Using a selective 5-hydroxytryptamine reuptake inhibitor, paroxetine, this study investigated the effect of indirect 5-hydroxytryptamine agonism on fasting small intestinal motility and transit. Eight healthy subjects were studied while receiving paroxetine 30 mg daily for five days and while receiving no treatment, in random order. Ambulant small intestinal motility was recorded from five sensors positioned from the duodenojejunal flexure to the ileum for 16-18 hours. Paroxetine reduced the migrating motor complex periodicity mean (SEM) from 81 (6) min to 67 (4) min (p < 0.05), and increased the propagation velocity of phase III from 3.1 to 4.7 cm/min in the proximal jejunum (p < 0.01), and from 1.6 to 3.4 cm/min distally (p < 0.001). Orocaecal transit time measured by lactulose hydrogen breath test was reduced by paroxetine from 70 (9) min to 48 (7) min (p < 0.05). These data suggest that 5-hydroxytryptamine participates in the control of migrating motor complexes in humans, and that selective 5-hydroxytryptamine reuptake inhibitors have a prokinetic action in the human small intestine.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Taniguchi, H., Ariga, H., Zheng, J., Ludwig, K., Mantyh, C., Pappas, T. N., Takahashi, T. (2008). Endogenous ghrelin and 5-HT regulate interdigestive gastrointestinal contractions in conscious rats. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G403-G411 [Abstract] [Full Text]  
• Foley, K. F., Pantano, C., Ciolino, A., Mawe, G. M. (2007). IFN-{gamma} and TNF-{alpha} decrease serotonin transporter function and expression in Caco2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G779-G784 [Abstract] [Full Text]  
• Chial, H. J., Camilleri, M., Burton, D., Thomforde, G., Olden, K. W., Stephens, D. (2003). Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G130-G137 [Abstract] [Full Text]  
• Camilleri, M (2002). Serotonergic modulation of visceral sensation: lower gut. Gut 51: i81-86 [Abstract] [Full Text]  
• Jones, J, Boorman, J, Cann, P, Forbes, A, Gomborone, J, Heaton, K, Hungin, P, Kumar, D, Libby, G, Spiller, R, Read, N, Silk, D, Whorwell, P (2000). British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47: ii1-19 [Full Text]  
• Tack, J, Coulie, B, Wilmer, A, Peeters, T, Janssens, J (1998). Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 42: 36-41 [Abstract] [Full Text]  
• Bearcroft, C P, Perrett, D, Farthing, M J G (1998). Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42: 42-46 [Abstract] [Full Text]  
• Bailey, J. E., Potokar, J., Coupland, N., Nutt, D. J. (1995). The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. J Psychopharmacol 9: 137-141 [Abstract]